Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

24432 ARTÍCULOS , VIENDO DEL 23026 AL 23040

[Neurobiological potential of astragaloside IV and prospects for its use in the treatment of Alzheimer's disease]

Berezutsky MA, Durnova NA, Kurchatova MN, Matvienko UA.

Zh Nevrol Psikhiatr Im S S Korsakova. 2025;125(2):7-12. doi: 10.17116/jnevro20251250217.

Safety and effectiveness of the anti-amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer's disease: The pharmacovigilance perspective

Bobbins A, Davies M, Lynn E, Roy D, Yeomans A, Shakir SAW.

Br J Clin Pharmacol. 2025 May;91(5):1352-1360. doi: 10.1002/bcp.70021. Epub 2025 Mar 6.

Bioactive peptides as multipotent molecules bespoke and designed for Alzheimer's disease

Mesias A, Borges S, Pintado M, Baptista-Silva S.

Neuropeptides. 2025 Jun;111:102515. doi: 10.1016/j.npep.2025.102515. Epub 2025 Mar 4.

Insulin resistance in Alzheimer's disease: signalling mechanisms and therapeutics strategies

Dahiya M, Yadav M, Goyal C, Kumar A.

Inflammopharmacology. 2025 Apr;33(4):1817-1831. doi: 10.1007/s10787-025-01704-2. Epub 2025 Mar 10.

Cellular Prion Protein and Amyloid-β Oligomers in Alzheimer's Disease-Are There Connections?

Fułek M, Hachiya N, Gachowska M, Beszłej JA, Bartoszewska E, Kurpas D, Kurpiński T, Adamska H, Poręba R, Urban S, Fułek K, Leszek J.

Int J Mol Sci. 2025 Feb 27;26(5):2097. doi: 10.3390/ijms26052097.

Going beyond ATP binding site as a novel inhibitor design strategy for tau protein kinases in the treatment of Alzheimer's disease: A review

Zaater MA, El Kerdawy AM, Mahmoud WR, Abou-Seri SM.

Int J Biol Macromol. 2025 May;307(Pt 3):142141. doi: 10.1016/j.ijbiomac.2025.142141. Epub 2025 Mar 14.

The role of n-3-derived specialised pro-resolving mediators (SPMs) in microglial mitochondrial respiration and inflammation resolution in Alzheimer's disease

Slayo M, Rummel C, Singhaarachchi PH, Feldotto M, Spencer SJ.

Mol Neurodegener. 2025 Mar 21;20(1):35. doi: 10.1186/s13024-025-00824-1.

GSK-3β dysregulation in aging: Implications for tau pathology and Alzheimer's disease progression

Rekha A, Afzal M, Babu MA, Menon SV, Nathiya D, Supriya S, Mishra SB, Gupta S, Goyal K, Rana M, Ali H, Imran M.

Mol Cell Neurosci. 2025 Jun;133:104005. doi: 10.1016/j.mcn.2025.104005. Epub 2025 Mar 20.

Deciphering T Cell Dynamics in Alzheimer's Disease Pathogenesis: Insights and Implications

Yang Q, Qiu Y, Ni J, Li H, Qing H.

Curr Neuropharmacol. 2025;23(12):1533-1550. doi: 10.2174/011570159X350611250303044527.

Microglia efferocytosis: an emerging mechanism for the resolution of neuroinflammation in Alzheimer's disease

Chen Y, Kou Y, Ni Y, Yang H, Xu C, Fan H, Liu H.

J Neuroinflammation. 2025 Mar 30;22(1):96. doi: 10.1186/s12974-025-03428-0.

Mitochondrial Genome Variants and Alzheimer's Disease

Kozin MS, Kulakova OG, Kiselev IS, Semina EV, Kakotkin VV, Agapov MA, Favorova OO.

Biochemistry (Mosc). 2025 Jan;90(Suppl 1):S146-S163. doi: 10.1134/S0006297924603174.

CaMKII mechanisms that promote pathological LTP impairments

Larsen ME, Rumian NL, Quillinan N, Bayer KU.

Curr Opin Neurobiol. 2025 Jun;92:102961. doi: 10.1016/j.conb.2024.102961. Epub 2025 Mar 31.

Ferroptosis and Alzheimer's: unveiling new avenues for the treatment and prevention

Sharma V, Sharma P, Singh TG.

Metab Brain Dis. 2025 Apr 1;40(4):167. doi: 10.1007/s11011-025-01587-w.

Knowledge and Attitude of Nurses in Wuxi, China Towards Alzheimer's Disease: A Cross-Sectional Study

Wang R, Gu Y, Yang H, Ge S, Cai Y, Wan X.

Nurs Open. 2025 Apr;12(4):e70199. doi: 10.1002/nop2.70199.

The endocannabinoid system offers a target for Alzheimer's disease treatment through inhibition of fatty acid amide hydrolase (FAAH)

de Ceballos ML.

FEBS J. 2025 Aug;292(16):4156-4159. doi: 10.1111/febs.70082. Epub 2025 Apr 2.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias